KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Equity Ratio (2016 - 2026)

West Pharmaceutical Services has reported Equity Ratio over the past 18 years, most recently at 0.73 for Q1 2026.

  • Quarterly Equity Ratio fell 1.88% to 0.73 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.73 through Mar 2026, down 1.88% year-over-year, with the annual reading at 0.74 for FY2025, 1.03% up from the prior year.
  • Equity Ratio was 0.73 for Q1 2026 at West Pharmaceutical Services, down from 0.74 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.76 in Q3 2023 and troughed at 0.71 in Q1 2022.
  • The 5-year median for Equity Ratio is 0.74 (2025), against an average of 0.74.
  • Biggest five-year swings in Equity Ratio: increased 6.3% in 2022 and later fell 2.14% in 2024.
  • Tracing WST's Equity Ratio over 5 years: stood at 0.74 in 2022, then rose by 1.34% to 0.75 in 2023, then decreased by 2.14% to 0.74 in 2024, then grew by 1.03% to 0.74 in 2025, then fell by 2.17% to 0.73 in 2026.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.73, 0.74, and 0.74 for Q1 2026, Q4 2025, and Q3 2025 respectively.